LabGenius

Biologics & Biosimilars · Oncology Therapeutics

Facts

as of Nov 19, 2026

LabGenius Therapeutics is pioneering a closed-loop platform that combines AI, robotic automation, and synthetic biology to accelerate the discovery of next-generation therapeutic antibodies for solid tumours.

Employees
51-200estimated range
Official records
Wikidata Q56585160

These are the key facts about LabGenius on Alion as of Nov 19, 2026. The latest round is Series A of $10M, announced in 2019.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$10MTotal raised
Series ALatest round
1Rounds and grants
Money by yearUSD, rounds and grants
2019$10M1 record
Largest rounds and grants
$10M
Sources: funding announcements, grant and company registers

Money

LabGenius has $10M paid in by investors, lenders and donors.

$10MPaid in
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
Equity raised
Oct 2019 · Series A
$10MPaid
Taxes
No public tax figures for this company or its entities.
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Owners & entities

Sources name Obvious Ventures, Lux Capital among the owners or investors of LabGenius.

Named investors, no share stated2
Holders and shares as each register or filing states them.

Milestones

Each milestone is dated by its source: registers, filings, the press